Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.


BACKGROUND To estimate the benefits of prostate-specific antigen (PSA) screening on prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations with a well-defined difference in intensity of screening. METHODS Between 1997 and 1999, a total of 11,970 men, aged 55-74 years, were included in the intervention arm of the European… (More)
DOI: 10.1016/j.ejca.2009.09.008

3 Figures and Tables


  • Presentations referencing similar topics